Gliomas frequently exhibited concurrent aberrations in these pathways, with glioblastoma having an average of 2.8 pathways affected (median: 3), IDH1/2-mutant astrocytoma with 1.7 (median: 1), and oligodendroglioma with 1.5 (median: 1, Supplementary Material 4). This evidence concerns the gene IDH1 and central nervous system cancer.